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Summary:
Fifty patients affected by sickle cell anaemia underwent
transplantation of HLA-identical haematopoietic stem
cells (bone marrow, 48; cord blood, 2). Two groups of
patients were considered for transplantation. Group 1
included 36 permanent residents of a European country
who, retrospectively, met the inclusion criteria accepted
at a consensus conference held in Seattle in 1990, wher-
ein children were selected because they already had evi-
dence of a morbid course. Group 2 included 14 patients
who were transplanted earlier, had not received more
than three blood transfusions and were transplanted
because they had decided to return to their country of
origin. Kaplan–Meier estimates of overall survival,
event-free survival and disease-free survival at 11 years
of the whole grafted population are 93, 82 and 85%,
respectively. In group 1, overall survival, EFS and DFS
were 88, 76 and 80% and in group 2, 100, 93 and 93%,
respectively. Clinical manifestations of the disease, as
well as disease associated haemolytic anaemia, disap-
peared in all successfully treated patients. Recovery of
spleen function was present in seven out of 10 evaluated
patients. Adverse events (death, absence of engraftment,
mixed chimerism and relapse) occurred more fre-
quently in group 1 than in group 2 (25% vs 7%,
P , 0.001). Acute graft-versus-host disease (GVHD)
was present in 20 patients (grade I or II, 19; grade III,
1), chronic GVHD in 10 (limited, 7; extensive, 3). One
patient developed an acute myeloid leukaemia. Gonadal
dysfunction was present in all patients (six boys and
eight girls) transplanted close to or after puberty,
although transient in one adolescent girl.
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In a prospective study of the Cooperative Study of Sickle
Cell Disease based on 3764 patients, it was shown that life
expectancy in patients suffering from sickle cell disease,
was decreased by 25 to 30 years, as compared with the
black American population in general.1 These results
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applied to a population with optimal health care. However
the morbidity remained severe and increased with age.
Preventive and supportive measures were the main thera-
peutic tools available until the last decade. Recently, hyd-
roxyurea has been shown to improve the clinical course in
both adults and children.2,3 However, bone marrow trans-
plantation remains the definitive treatment for cure and
eradication of the disease. The first patient cured of sickle
cell anaemia had been transplanted for an acute myeloid
leukaemia.4 Our group was the first to propose bone mar-
row transplantation for sickle cell anaemia per se.5,6 How-
ever the unpredictable course of the disease has led to the
establishment of selection criteria to avoid submitting a
mildly affected child to a potentially dangerous procedure.7
In the present study, we compare a population of severely
affected patients with a population of children mildly affec-
ted by the disease, in whom transplantation was done
before the occurrence of severe symptoms.
Patients, donors and methods
Fifty patients (27 females, 23 males) with homozygous sic-
kle cell anaemia (haemoglobin genotype S/S) were trans-
planted in four Belgian centres between April 1986 and
January 1997. Informed consent of the parents and/or the
patients was obtained. The countries of origin were Demo-
cratic Republic Congo (formerly Zaire), 43; Cameroon, 3;
Nigeria, 2; Burundi, 1; and Central Republic of Africa, 1.
Age at the time of transplantation ranged from 0.9 to 23
years (median, 7.5) and the follow up from 0.3 to 11 years
(median, 5).
Group 1 included 36 patients (18 females, 18 males, age
range, 1.7 to 23 years) with a median age of 8.6 years. They
were transplanted because of the severity of their disease.
Retrospectively, they indeed fulfilled the inclusion criteria7
of severity (frequent painful crises, 36; seizures or strokes,
6; acute chest syndrome, 20; osteonecrosis, 3). Two patients
did not fulfill the criteria of age (less than 16 years). They
were two female students (17 and 23 years old), who
decided to undergo transplantation, well aware of the
inherent risks of the procedure, but unable to accept the
morbidity of the disease.
Group 2 included 14 patients (nine females, five males,
age range, 0.9 to 15 years) with a median age of 2 years.
This group included asymptomatic patients, transplanted at
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a young age since their family had to return to Africa where
medical care would not be optimal. The patients in this
group had had minimal symptoms (painful episodes but no
acute chest syndrome, no seizure nor stroke, no priapism,
no chronic organ damage) and no more than three blood
transfusions before transplantation.
Donors were HLA-genoidentical siblings in 49 patients.
For one patient, the donor was the HLA-phenoidentical
father. The source of stem cells was bone marrow in 48
patients, cord blood in two.
The conditioning regimen consisted of busulfan,
16 mg/kg, and cyclophosphamide, 200 mg/kg (Bu16/
Cy200) in 22 patients, Bu16/Cy200/total lymphoid
irradiation (TLI) in six, Bu16/Cy200/anti-thymocyte globu-
lins (ATG) in 14, Bu14/Cy200 in six, and Bu
500 mg/m2/Cy200 in two patients. The dose of TLI was
750 cGy in one fraction over 6 h with 18 MV X-rays pro-
duced by linear acceleration (the lungs being shielded). TLI
was given in patients heavily transfused to reduce the risk
of rejection. Later, TLI was replaced by ATG. The dose of
ATG (Fresenius; Hoechst Marion Roussel, Belgium) was
15 to 90 mg/kg divided in three doses before transplan-
tation.
The patient who underwent a second bone marrow trans-
plantation was conditioned by a regimen previously
described by Storb et al8 containing cyclophosphamide,
ATG and a thoraco-abdominal irradiation.
Following the observation of a high incidence of neuro-
logical events post-transplantation,9 13 patients received a
neurological prophylaxis consisting of anticonvulsant drugs
(phenytoin or carbamazepine). In addition, these patients
received blood transfusions to maintain the platelet count
above 50 · 109/l and Hb levels between 90 and 110 g/l.
Strict control of blood pressure values, cyclosporin A and
magnesium levels were reinforced.9,10
To prevent GVHD, 25 patients were given cyclosporin
A alone for a period of 6 to 18 months and 25 cyclosporin
A together with a short course of methotrexate.
Acute GVHD was treated by steroids. Chronic GVHD
required the use of azathioprine (four patients) and thalido-
mide (four patients).
Prophylaxis of infections included gut decontamination
and infusions of immune globulins during the first year
post-transplantation. It was suggested that penicillin should
be continued until recovery of spleen function.
Chimerism studies were performed by at least one of the
following methods: cytogenetics when donor and recipient
were of the opposite sex, residual levels of HbS when the
donor had a A/A genotype of the Hb and studies of variable
numbers of tandem repeats in DNA if donor and recipient
were of the same sex.
The Lansky scale was used to measure the functional
status of the patients instead of the Karnofsky score,
because it gives a better description of children’s activities
(100–80, able to carry on normal activities, no special care
is needed; 70–50, mild to moderate restriction; 40–10,
moderate to severe restriction).
Statistical analysis
The Kaplan–Meier method was used to calculate overall
survival, event-free survival and disease-free survival.
Events included deaths, absence of engraftment, rejection
and recurrence of the disease. Disease-free survival was
defined by the absence of clinical and biological signs and
symptoms of sickle cell anaemia. Comparison of the per-
centage of events was done using the Fisher’s exact test.
The Wilcoxon rank-sum test was used to assess the signifi-
cance of the difference of age in groups 1 and 2.
Results
Engraftment and survival
Among the 50 patients, engraftment occurred in 47. The
median time to obtain an ANC .0.5 · 109/l was 19 days
(range, 11–32); the median time to achieve a platelet count
.50 · 109/l, without platelet support, was 20 days (range,
10–108). Three patients never presented any sign of
engraftment (Table 1). They were 6, 7 and 14 years old at
the time of transplantation; two of them were on a chronic
transfusion program for acute chest syndrome or strokes;
the third patient had suffered vaso-occlusive crises and had
been transfused more than three times. The number of
nucleated cells infused in these three patients was two (one
patient), and 4 · 108 cells/kg (two patients). The condition-
ing regimen consisted of Bu14/Cy200 in one patient and
Bu16/Cy200/ATG in two patients. These patients remained
free of symptoms for several years after autologous recov-
ery, due to a persistent high level of HbF.11
Rejection occurred in two patients: the first patient
rejected the graft, between day 30 and 60, although initial
engraftment had been confirmed by cytogenetic studies.
The donor was the father and a second successful bone
marrow transplantation was performed on day 60, from the
same donor. This patient was in group 1.
The second rejection occurred 18 months after bone
Table 1 Results of transplantation in sickle cell anaemia according to
the patient’s status at the time of the procedure
Group 1a Group 2b P value
No. patients 36 14
Sex: F/M 18/18 9/5
Age (years), median (range) 8.6 (1.7–23) 2.0 (0.9–15) 0.0016
No. RBC transfusions .3 <3
Survival 34 14
Deaths 2 0
Absence of engraftment 3 0
Relapse 1 1
Mixed chimerism (.30% 3 0
recipient cells)
Total (%) 9 (25) 1 (7) ,0.001
Acute GVHD grade I–II 14 5
Actue GVHD grade III–IV 1 0
Chronic GVHD limited 5 2
Chronic GVHD extensive 3 0
aGroup 1, patients severely affected by sickle cell anaemia at the time
of transplantation.
bGroup 2, patients transplanted at an early stage of the disease.
GVHD = graft-versus-host disease.
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marrow transplantion in a 4-year-old boy, conditioned with
Bu14/Cy200. This patient was in group 2.
Mixed chimerism was present in six patients. In three,
mixed chimerism was stable with less than 10% of recipient
cells. In three patients, the percentage of recipient cells was
respectively 35, 30 and 50%, 6, 13 and 60 months after
transplantation. Those three patients belong to group 1.
Forty-eight patients are alive 4 months to 11 years after
transplantation with a median follow up of 5 years. Two
patients died: one patient died 3 months after bone marrow
transplantation of acute GVHD complicated by CMV and
Aspergillus infections; the other patient died 6 years after
transplantation of a sudden death at the age of 16. The
patient had been asymptomatic since transplantation with
a normal level of Hb and a complete chimerism (100%
donor cells).
Overall, the survival probability is 93%. In groups 1 and
2, overall survival probabilities are respectively 88 and
100% (Figure 1).
The event-free survival for the 50 patients is 82%. In
groups 1 and 2, EFS are 76 and 93%, respectively
(Figure 1). The disease-free survival for the 50 patients is
85%. In groups 1 and 2, DFS are 80 and 93%, respect-
ively (Figure 1).
Cord blood transplantation was performed in two
patients aged 5 and 3 years. Engraftment was slow but
present. Growth factors (filgrastim; Amgen Roche,
Belgium) were used from day 23 and 17, respectively.
Clinical data, number of cells infused and time for recovery
are summarised in Table 2. Acute GVHD was not present
but the 5-year-old girl developed de novo chronic GVHD
18 months after cord blood transplantation, when cyclospo-
rin A was stopped. It was a lichenoid type of chronic
GVHD affecting only the skin and confirmed by a biopsy.
PUVA were not effective. These two patients had a level
of fetal hemoglobin decreasing slowly during the first
months, in accordance with the intrinsic properties of stem
cells of cord blood origin.12
Transplant-related morbidity
Graft-versus-host disease: Grade I acute GVHD was
detected in 10 patients, grade II in nine and grade III in
one. Chronic GVHD was diagnosed in 10 patients, being
limited in seven patients and extensive in three patients.
Two patients with chronic GVHD developed mild dyspnea
related to Bronchiolitis obliterans. This was confirmed by
CT scan and pulmonary function tests. Four patients
developed severe GVHD (one acute grade III and three
chronic and extensive). The four patients were in group 1.
Neurological complications: Eighteen patients had seiz-
ures after transplantation, five occurred in 13 patients
receiving anticonvulsant therapy, while 13 occurred in the
37 not receiving prophylaxis (38 vs 35%). Among the 18
patients, four presented with a history of seizures or strokes
before transplantation. In the group of 32 patients who did
not present neurological complications, two had a history
of seizures before transplantation. There was no recurrence
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Figure 1 (a) Overall survival (——), EFS (– – –) and DFS (. . . .) in 50
patients transplanted in Belgium for sickle cell anaemia. The results were
respectively 93, 82 and 85%. (b) Overall survival (——), EFS (– – –) and
DFS (. . . .) in group 1 (36 patients transplanted in Belgium for sickle cell
anaemia and severely affected). The results were respectively 88, 76 and
80%. (c) Overall survival (——), EFS (– – –) and DFS (. . . .) in group 2
(14 patients transplanted in Belgium for sickle cell anaemia early in the
course of their disease). The results were respectively 100, 93 and 93%.
Long-term benefits and side-effects
Forty-five patients had stable engraftment. Disease associa-
ted manifestations as well as haemolytic anaemia disap-
peared in all of them. The Lansky scale was 100 for all
patients, it was 90 in two patients with Bronchiolitis oblit-
erans and 60 in one patient with chronic GVHD and acute
myeloid leukemia.
Fourteen patients (28%) returned to their country of ori-
gin, 12 months to 5 years after transplantation (median,
21 months).
Growth was normal or even improved after transplan-
tation except in two patients who received intensive
immune suppression including steroids for chronic GVHD.
Thyroid function was normal in 27 of the 28 evaluated
patients. One patient had normal levels of thyroid hormones
with an elevated TSH level. This patient received a con-
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Table 2 Cord blood transplantations in sickle cell anaemia
Recipient UPN 38 UPN 43
Sex F F
Age (years) 5.5 3.1
Weight (kg) 23.5 16.1
Cord blood
origin HLA-id sister HLA-id sister
volume (ml) 141 100
nucleated cells (· 107/kg) 4.6 4.7
CD34 ( · 105/kg) 0.9 0.9
CFU-GM (· 104/kg) 3.3 3.6
Engraftment
ANC (.0.5 · 109/l) day 32 day 31
Platelets (.50 · 109/l) day 48 day 54
Chimerism 100% donor 100% donor
GVHD
acute 0 0
chronic 0 skin (lichenoid)
UPN = unique patient number; GVHD = graft-versus-host disease.
ditioning regimen including Bu16/Cy200, without TLI. He
developed chronic GVHD with Bronchiolitis obliterans.
The two girls transplanted after puberty, at the ages of
17 and 23, developed secondary amenorrhoea. Levels of
LH, FSH and oestradiol were measured in one (UPN 22)
and are shown in Table 3. If we consider that the menarche
occurs around the age of 15 in sickle cell patients, six other
girls were evaluable: five had primary amenorrhoea and
delayed sexual maturation. All these patients required hor-
monal substitution. One patient had a spontaneous men-
arche at the age of 15. The levels of LH and FSH were
increased at that time. Later, at the age of 17, she had nor-
mal levels of LH, FSH and estradiol (Table 3).
The six adolescent boys evaluated had normal sexual
development, but four had decreased levels of testosterone,
four increased levels of FSH and one an increased level of
LH (Table 4). Fertility was not tested.
Osteonecrosis of hips and shoulders was present in three
patients aged 15, 17 and 23 years at the time of transplan-
tation. There was no improvement on X-rays, 3 years after
bone marrow transplantation.
Spleen function was prospectively studied by isotopic
Table 3 Gonadal function in adolescent girls after bone marrow transplantation for sickle cell anaemia
Age at BMT Preparative regimena Age at evaluation Amenorrhoea LH (mU/ml) FSH (mU/ml) Estr (pg/ml N,
(years) (years) N, 1–13 N, 1–24 .35
UPN4 9 BuCyTLI 18 primary secondary 37.2 105 ,10
UPN12 23 BuCy ND primary ND ND ND
UPN14 12 BuCyTLI 19 spont menb 23.5 97.7 ,10
UPN15 10 BuCy 15 49 51 15
17c 5.9 5.1 121
UPN21 13 ByCyATG 18 primary 75 94 ,10
UPN22 17 ByCyTLI 22 secondary 88 160 ,10
UPN28 15 ByCyATG 17 primary 21 110 ,10
UPN40 12 ByCyATG 15 primary 24 33 ,10
aBu, busulfan; Cy, cyclophosphamide; TLI, total lymphoid irradiation; ATG, anti-thymocyte globulins.
bSpontaneous menarche.
cUPN15, measurements done at the age of 17 giving normal values.
UPN = unique patient number.
Table 4 Gonadal function in adolescent boys after bone marrow trans-
plantation for sickle cell anaemia
Age at Preparative Age at LH FSH Testo
BMT regimena evaluation (mU/ml) (mU/ml) (nm/l) N,
(years) (years) N, 1–10 N, 1–8 13–35
UPN6 7 BuCy 16 4.6 4.4 10.7
UPN23 13 BuCyTLI 17 2.4 11.6 6.6
UPN24 11 BuCyTLI 16 2.8 10.9 9.1
UPN29 14 BuCyATG 18 11 13 ND
UPN32 15 BuCyATG 17 5.4 10.9 16
UPN39 15 BuCyATG 17 2.3 7.9 14.2
aBu, busulfan; Cy, cyclophosphamide; TLI, total lymphoid irradiation;
ATG, anti-thymocyte globulins; UPN = unique patient number;
ND = not determined.
studies, using Tc-99m-RBC and Cr-51 heat-damaged red
blood cells, in 10 patients. Their ages ranged from 2.4 to
17 years at the time of transplantation (median, 13 years).
In seven patients, an increase of the splenic red cell pool
was seen between 3 months and 3 years after transplan-
tation. Two of these seven patients also had an improve-
ment of the phagocytosis of heat-damaged red blood cells.
Three patients did not improve their splenic function: the
first one was transplanted at the age of 17 years and the
last test was done at the age of 21; the second patient had
a decrease in his splenic function. He was transplanted at
the age of 2.4 years and still had some residual function at
that time. Later he developed severe chronic GVHD,
received intensive immune suppression and developed a
myelodysplasia and acute myeloid leukaemia. When the
spleen function was tested 3 years after transplantation,
there was an absence of splenic tissue on the isotopic stud-
ies. The third patient was transplanted at the age of 5 years.
He developed a localised chronic GVHD and had no detect-
able spleen function 2 years after transplantation.
One patient with extensive chronic GVHD required ster-
oids, cyclosporin A and azathioprine for 4 months, and thal-
idomide for 30 months. He developed a myelodysplasia 35
months after bone marrow transplantation and 18 months
later an acute myeloid leukaemia. The marrow cells were
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all of donor origin. He first responded to low-dose Ara-C
but now has refractory leukaemia.
Discussion
This series summarises the experience of haematopoietic
stem cell transplantation for sickle cell anaemia in Belgium.
One centre elected to transplant children early during the
course of their disease, before their return to Africa (group
2). The other centres elected to graft more severely affected
patients (group 1). The study showed the advantage of an
early intervention. The rate of non-engraftment, mixed
chimerism (more than 30% recipient cells), and rejection
was higher in group 1 as compared to group 2 (25 vs 7%,
P , 0.001). GVHD was also more frequently diagnosed in
group 1. This might be associated with the fact that the
patients in this group were older than in group 2 (median
age, 8.6 vs 2.0 years, P value, 0.0016). Other studies have
also found that the incidence of acute and chronic GVHD
was remarkably low in the youngest recipients.13
A total of 102 patients with sickle cell disease has been
transplanted in Belgium, France,14 the United Kingdom
(personal communication), Italy,15 Germany (personal
communication) and Switzerland (personal commun-
ication) (Table 5). Current Kaplan–Meier estimates of over-
all survival, EFS and DFS are 90, 79 and 81% respectively
(Figure 2). In the USA, 32 children were transplanted for
sickle cell anaemia, with estimates of overall survival and
EFS of 92% and 76%, respectively.16
For the 45 patients transplanted in Belgium, with stable
engraftment, disease-related clinical symptoms disappeared
totally in all of them. For the four patients who had an
autologous recovery, an increase in foetal haemoglobin was
seen in three out of four, which lasted for several years after
transplantation and resulted in the absence of symptoms.11
Hydroxyurea was started when symptoms recurred,
between 3 and 4 years after transplantation.
Seizures after transplantation are a common side-effect
and the use of a prophylactic scheme has been proposed to
Table 5 Haematopoietic stem cell transplantation in sickle cell anae-
mia: European data
No. Deaths No Second Alive





Belgium 50 2 5 1 44
France14 26 2 4 1 21
UKa 15 2 0 0 13
Italy15 6 3 0 0 3
Germanyb 3 0 1 ongoing 2
Switzerlandc 2 0 0 0 2
Total 102 9 10 2 85
Unpublished data obtained by personal communication with aIrene Roberts






















Figure 2 Overall survival (——), EFS (– – –) and DFS (. . . .) in 101
patients transplanted in Europe for sickle cell anaemia. The results were
respectively 88, 76 and 80%.
prevent these complications.9 Recovery of the spleen func-
tion was demonstrated in seven out of 10 patients evalu-
ated. Osteonecrosis did not improve on X-ray, although
healing has been shown by others.14 Growth and thyroid
function were normal in the vast majority of patients.
Gonadal dysfunction appeared in all girls transplanted
between the ages of 9 and 23 years, although it was transi-
ent in one. Boys present normal sexual maturation but most
of them had abnormal LH, FSH or testosterone levels
which is biochemical evidence of Leydig cell damage.
None of them required hormonal replacement therapy. Bus-
ulfan is known to induce gonadal insufficiency and this
should be discussed with the patient and their relatives.17
It remains to be determined if patients transplanted early
in life will also develop gonadal failure. The disorder was
transient in one of our patients and a successful pregnancy
after bone marrow transplantation for thalassaemia, using
the same conditioning regimen, has been reported.18
It is now well accepted that stem cell transplantation is
an approach which can eradicate the disease and cure a
patient with sickle cell anaemia. However, the timing of
transplantation remains a dilemma.19,20 Unfortunately, the
course of the disease is often unpredictable. The only sig-
nificant prognostic factor is the level of foetal haemoglobin
which is associated with a less severe outcome. Neither is
an early onset of symptoms predictive of the future course
of the disease, nor the absence of symptoms during the
first years of life. Haplotypes and co-inheritance of alpha
thalassaemia are not conclusive in the prediction of out-
come. Transcranial Doppler ultrasonography might be an
interesting tool to detect very early vascular damage at the
cerebral level.21
Opponents to early transplantation argue that such a pro-
cedure might be too toxic to treat mildly affected patients
who would almost never require health care. These rep-
resent probably 5% of sickle cell patients in the USA. For
the remaining 95%, only a small proportion will have a
HLA-identical sibling and will be candidates for transplan-
tation. Since the best results are obtained in very young
patients, we favour informing parents about the possibility
of bone marrow transplantation if a familial HLA-compat-
ible donor is available. This would give the child the best
chance to be cured. In this young population, the risk of
rejection is less than 5%,22,23 while the risk of GVHD is
below 20%.24 In addition, transplant-related mortality due
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to cerebral haemorrhages was shown to be less frequent in
young patients without vascular damage.9 Furthermore, if
patients have been heavily transfused, alloimmunization to
platelets will make the prevention and therapy of cerebral
haemorrhage more difficult.22 The use of alkylating agents,
cyclophosphamide and busulfan, included in the condition-
ing regimen has been associated with ovarian failure, as
well as testicular dysfunction. The consequences of such
preparative regimens on gonads when given early in life
remain to be determined. Furthermore, the social inte-
gration of sickle cell patients could be optimal since the
first years of life with proper education, absence of depen-
dence upon others as a consequence of a chronic illness,
self-confidence instead of fear of unpredictable and painful
problems, and later, the possibility of competing effectively
for jobs.
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